Pharmaceutical company, Sun Pharmaceutical Industries Ltd, announced on Friday (June 13) the appointment of Kirti Ganorkar as its new managing director, effective September 1, 2025. This decision is part of a planned leadership transition, with Founder Dilip Shanghvi remaining in his role as executive chairman of the board.
Pending shareholder approval at the upcoming annual general meeting, Ganorkar will oversee the company’s complete business and functional operations. With a background as a chemical engineer and an MBA, he joined Sun Pharma in 1996.
Since June 2019, Ganorkar has been leading the company’s India division and has successfully increased its market share. He has previously held various leadership positions in business development, marketing, M&A, new product launches, project management, IP, and litigation within Sun Pharma.
Also Read: Sun Pharma Q4 Results: Profit falls short of expectations, revenue rises 8% YoY; ₹5.50 dividend declared
He has been instrumental in the company’s entry into specialty pharmaceuticals, securing rights for innovative products like Ilumya. Ganorkar also played a key role in Sun Pharma’s expansion into Japan and laid the initial groundwork for its presence in Europe. He has provided significant support to the US business, overseeing numerous notable generic projects from conception to commercialization.
Ganorkar stated, “Participating in the company’s evolution into a leading global pharmaceutical entity has been an immensely rewarding journey. I am optimistic about the company’s ongoing success.”
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, remarked, “Kirti has consistently showcased effective leadership across diverse roles at Sun. I firmly believe in his capability to guide the company into its next growth phase, and I extend my best wishes for his success.”
Also Read: Sun Pharma plans to enhance specialty focus, pursuing further acquisitions
As executive chairman, Shanghvi will continue to lead the board and contribute to shaping the company’s long-term strategy.
Shares of Sun Pharmaceutical Industries Ltd closed at ₹1688.70, an increase of ₹1.70, or 0.10%, on the BSE.
(Edited by : Shoma Bhattacharjee)
